SXTP: 60 Degrees Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.01
Enterprise Value ($M) 10.06
Book Value ($M) 7.13
Book Value / Share 0.58
Price / Book 0.42
NCAV ($M) 6.65
NCAV / Share 0.54
Price / NCAV 0.45

Profitability (mra)
Return on Invested Capital (ROIC) -0.10
Return on Assets (ROA) -0.10
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 6.77
Current Ratio 7.16

Balance Sheet (mrq) ($M)
Current Assets 7.91
Assets 8.38
Liabilities 1.25
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.25
Operating Income -5.15
Net Income -3.77

Cash Flow Statement (mra) ($M)
Cash From Operations -4.54
Cash from Investing -0.12
Cash from Financing 6.47

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
05-07 13G/A Knight Therapeutics (Barbados) Inc. 9.97 4.11

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT P
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(
2023-11-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPO
2023-08-25 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-18 271,315 753,057 36.03
2024-07-17 22,832 107,384 21.26
2024-07-16 25,951 144,754 17.93
2024-07-15 18,280 155,799 11.73

(click for more detail)

Similar Companies
SPRC – SciSparc Ltd. SRZN – Surrozen, Inc.
SXTC – China SXT Pharmaceuticals, Inc. SYBX – Synlogic, Inc.
TCON – TRACON Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io